Texas Permanent School Fund increased its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 3.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,031 shares of the life sciences company’s stock after purchasing an additional 1,766 shares during the period. Texas Permanent School Fund’s holdings in Integra Lifesciences were worth $2,676,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of Integra Lifesciences by 104.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,064 shares of the life sciences company’s stock valued at $18,251,000 after acquiring an additional 141,368 shares during the period. Nordea Investment Management AB purchased a new stake in shares of Integra Lifesciences in the 3rd quarter valued at approximately $5,089,000. Retirement Systems of Alabama raised its stake in shares of Integra Lifesciences by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 91,666 shares of the life sciences company’s stock valued at $4,134,000 after acquiring an additional 352 shares during the period. Legacy Financial Advisors Inc. purchased a new stake in shares of Integra Lifesciences in the 4th quarter valued at approximately $33,000. Finally, Campbell Newman Asset Management Inc. raised its stake in shares of Integra Lifesciences by 11.6% in the 4th quarter. Campbell Newman Asset Management Inc. now owns 9,060 shares of the life sciences company’s stock valued at $409,000 after acquiring an additional 944 shares during the period. Institutional investors and hedge funds own 84.29% of the company’s stock.
Shares of IART stock traded up $0.06 during trading on Friday, reaching $50.27. The company’s stock had a trading volume of 33,850 shares, compared to its average volume of 534,739. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.86 and a current ratio of 2.86. The stock has a market capitalization of $4.26 billion, a P/E ratio of 20.77, a price-to-earnings-growth ratio of 1.44 and a beta of 0.90. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $67.50.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.04. The firm had revenue of $359.69 million during the quarter, compared to analysts’ expectations of $361.12 million. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.58 earnings per share. On average, research analysts forecast that Integra Lifesciences Holdings Corp will post 2.7 EPS for the current fiscal year.
In other news, Director Rhonda Germany Ballintyn purchased 1,933 shares of the stock in a transaction on Thursday, March 14th. The stock was bought at an average price of $56.08 per share, for a total transaction of $108,402.64. Following the acquisition, the director now directly owns 3,665 shares of the company’s stock, valued at approximately $205,533.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Richard E. Caruso sold 30,128 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $56.06, for a total transaction of $1,688,975.68. Following the transaction, the insider now owns 143,384 shares of the company’s stock, valued at approximately $8,038,107.04. The disclosure for this sale can be found here. Insiders sold 47,077 shares of company stock valued at $2,568,469 in the last 90 days. Company insiders own 4.50% of the company’s stock.
IART has been the topic of a number of research analyst reports. BidaskClub raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. JMP Securities reissued a “buy” rating and issued a $62.00 price target on shares of Integra Lifesciences in a research note on Wednesday, February 27th. Finally, Morgan Stanley set a $57.00 price target on shares of Integra Lifesciences and gave the company a “hold” rating in a research note on Friday, February 22nd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $59.42.
TRADEMARK VIOLATION NOTICE: “Texas Permanent School Fund Grows Stake in Integra Lifesciences Holdings Corp (IART)” was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thestockobserver.com/2019/05/17/texas-permanent-school-fund-grows-stake-in-integra-lifesciences-holdings-corp-iart.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
See Also: What is net income?
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.